The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
NCRI 2017 | Revolutionary immunotherapy for lymphoma
Immunotherapy has emerged in recent years as a promising lymphoma treatment, with exciting new drug classes being developed with innovative mechanisms of action. Here, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses various types of lymphoma treatment, including ADCC-activating monoclonal antibodies, antibody-drug conjugates, and traditional immunotherapies such as PD-1 inhibitors. Dr Collins reviews the efficacy of these drug types in both Hodgkin and non-Hodgkin lymphoma, and some of their specific subtypes, drawing conclusions from a range of sources, including the 2002 study by the French GELA group regarding the effectiveness of rituximab combined with CHOP in combatting diffuse large B-cell lymphoma and the subsequent long-term follow up. This video was recorded at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK.
